Web-Based Intervention for Cancer Pain in Breast Cancer Survivors
(CAI Trial)
Trial Summary
What is the purpose of this trial?
This study is funded by the HEAL Initiative (https://heal.nih.gov/). Based on Preliminary Studies (PSs), the research team developed and pilot-tested an evidence-based Web App-based information and coaching/support program for cancer pain management (CAPA) that was culturally tailored to Asian American breast cancer survivors using multiple unique features. However, CAPA rarely considered depressive symptoms accompanying pain in its design or components, and PSs indicated the necessity of further individualization of the intervention components of CAPA due to diversities in the needs of ABD. The purpose of the proposed 2-phase study is to further develop CAPA with additional components for ABD and the individual optimization functionality (CAI) and to test the efficacy of CAI in improving cancer pain experience of ABD. The specific aims are to: a) develop and evaluate CAI through an expert review and a usability test (R61 phase); b) determine whether the intervention group (that uses CAI and usual care) will show significantly greater improvements than the active control group (that uses CAPA and usual care) in primary outcomes (cancer pain management and cancer pain experience including depressive symptoms) from baseline to post 1-month and post 3-months; c) identify theory-based variables (attitudes, self-efficacy, perceived barriers, and social influences) that mediate the intervention effects of CAI on the primary outcomes; and d) determine whether the effects of CAI on the primary outcomes are moderated by selected background, disease, genetic, and situational factors. This study is guided by the Bandura's Theory and the stress and coping framework by Lazarus and Folkman. The R61 phase includes: (a) the intervention development process, (b) a usability test among 15 ABD, 15 family members, and 15 community gatekeepers; and (c) an expert review among 10 experts in oncology. The R33 phase adopts a randomized repeated measures control group design among 300 ABD. Long-term goals are: (a) to extend and test CAI in various healthcare settings with diverse subgroups of ABD, (b) examine the costeffectiveness, sustainability, and scalability of CAI in the settings, and (c) translate CAI into health care for ABD.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are in active depression treatment, you will be excluded from the R33 phase of the study.
What data supports the effectiveness of the treatment for cancer pain management in breast cancer survivors?
Research shows that web-based programs, like the one being studied, can help manage cancer pain by providing education and support. For example, a study found that a technology-based program improved pain management and quality of life in Asian American breast cancer survivors. Additionally, web-based pain coping skills training has been found acceptable and potentially beneficial for patients with persistent cancer pain.12345
Is the web-based intervention for cancer pain management safe for humans?
How is the Web-Based Intervention for Cancer Pain in Breast Cancer Survivors different from other treatments?
This treatment is unique because it uses a web-based platform to provide personalized education and self-management support for pain, focusing on improving understanding and management of pain through technology, which is particularly beneficial for breast cancer survivors who may have limited access to traditional pain management resources.124910
Research Team
Eun Ok Im
Principal Investigator
The University of Texas at Austin
Eligibility Criteria
This trial is for women over 18 who identify as Chinese, Korean, or Japanese; can read and write English or their native languages; have internet access; experienced cancer pain in the past week and depressive symptoms in the last two weeks. They must also have been diagnosed with breast cancer within the last five years.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
R61 Phase - Intervention Development
Development and evaluation of CAI through expert review and usability test
R33 Phase - Randomized Control Trial
Randomized repeated measures control group design to test CAI efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- CAI (Behavioural Intervention)
- CAPA (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas at Austin
Lead Sponsor
Dr. Elly Barry
University of Texas at Austin
Chief Medical Officer
MD from Harvard Medical School
Dr. Brian Windsor
University of Texas at Austin
Chief Executive Officer since 2023
PhD in Molecular Biology from the University of Texas at Austin